Kala Free Cash Flow vs Free Cash Flow Yield Analysis

KALA Stock  USD 6.21  0.25  3.87%   
Kala Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Kala Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kala Pharmaceuticals is a good investment. Please check the relationship between Kala Pharmaceuticals Free Cash Flow and its Free Cash Flow Yield accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kala Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.

Free Cash Flow vs Free Cash Flow Yield

Free Cash Flow vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kala Pharmaceuticals Free Cash Flow account and Free Cash Flow Yield. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Kala Pharmaceuticals' Free Cash Flow and Free Cash Flow Yield is -0.65. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Kala Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Kala Pharmaceuticals' Free Cash Flow and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of Kala Pharmaceuticals are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Free Cash Flow i.e., Kala Pharmaceuticals' Free Cash Flow and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

-0.65
Relationship DirectionNegative 
Relationship StrengthWeak

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.
Most indicators from Kala Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kala Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kala Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.At present, Kala Pharmaceuticals' Sales General And Administrative To Revenue is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 29.6 M, whereas Selling General Administrative is forecasted to decline to about 20.7 M.
 2021 2022 2023 2024 (projected)
Depreciation And Amortization2.3M860K303K287.9K
Interest Income104K664K2.5M2.6M

Kala Pharmaceuticals fundamental ratios Correlations

0.760.880.740.87-0.420.80.860.780.870.61-0.130.370.71-0.060.96-0.320.830.710.90.710.84-0.290.870.830.94
0.760.610.730.59-0.630.660.650.520.850.910.030.780.660.190.75-0.230.80.430.770.970.47-0.130.560.680.66
0.880.610.61.0-0.430.650.850.620.70.370.00.330.380.210.9-0.040.670.550.750.510.68-0.430.680.640.91
0.740.730.60.63-0.810.660.650.590.950.640.460.590.73-0.030.76-0.640.60.570.920.740.670.060.70.690.71
0.870.591.00.63-0.480.630.850.60.710.350.070.330.380.220.9-0.080.650.530.750.50.66-0.430.660.620.91
-0.42-0.63-0.43-0.81-0.48-0.3-0.45-0.26-0.67-0.48-0.74-0.77-0.49-0.24-0.540.43-0.31-0.05-0.58-0.58-0.160.04-0.21-0.27-0.5
0.80.660.650.660.63-0.30.830.370.750.44-0.190.380.65-0.40.76-0.450.560.770.750.590.68-0.420.680.870.74
0.860.650.850.650.85-0.450.830.380.740.37-0.050.360.62-0.150.92-0.350.590.640.760.560.61-0.660.610.730.94
0.780.520.620.590.6-0.260.370.380.690.58-0.070.190.550.060.68-0.20.780.460.750.560.790.270.840.590.64
0.870.850.70.950.71-0.670.750.740.690.780.210.560.79-0.020.87-0.550.810.660.980.870.76-0.020.810.820.81
0.610.910.370.640.35-0.480.440.370.580.780.00.620.620.230.55-0.240.810.380.70.960.460.220.570.570.43
-0.130.030.00.460.07-0.74-0.19-0.05-0.070.210.00.39-0.030.30.01-0.28-0.15-0.270.150.06-0.180.26-0.17-0.130.0
0.370.780.330.590.33-0.770.380.360.190.560.620.390.390.230.45-0.060.34-0.020.440.680.04-0.060.110.290.37
0.710.660.380.730.38-0.490.650.620.550.790.62-0.030.39-0.450.72-0.750.580.540.760.670.61-0.10.650.630.69
-0.060.190.21-0.030.22-0.24-0.4-0.150.06-0.020.230.30.23-0.45-0.050.580.16-0.28-0.060.18-0.180.17-0.13-0.28-0.1
0.960.750.90.760.9-0.540.760.920.680.870.550.010.450.72-0.05-0.340.770.60.880.690.73-0.40.750.770.99
-0.32-0.23-0.04-0.64-0.080.43-0.45-0.35-0.2-0.55-0.24-0.28-0.06-0.750.58-0.34-0.2-0.42-0.52-0.31-0.39-0.05-0.39-0.45-0.35
0.830.80.670.60.65-0.310.560.590.780.810.81-0.150.340.580.160.77-0.20.50.780.860.65-0.020.740.810.7
0.710.430.550.570.53-0.050.770.640.460.660.38-0.27-0.020.54-0.280.6-0.420.50.760.440.9-0.110.870.690.58
0.90.770.750.920.75-0.580.750.760.750.980.70.150.440.76-0.060.88-0.520.780.760.780.86-0.010.890.810.84
0.710.970.510.740.5-0.580.590.560.560.870.960.060.680.670.180.69-0.310.860.440.780.490.020.590.710.58
0.840.470.680.670.66-0.160.680.610.790.760.46-0.180.040.61-0.180.73-0.390.650.90.860.490.050.990.710.71
-0.29-0.13-0.430.06-0.430.04-0.42-0.660.27-0.020.220.26-0.06-0.10.17-0.4-0.05-0.02-0.11-0.010.020.050.09-0.19-0.47
0.870.560.680.70.66-0.210.680.610.840.810.57-0.170.110.65-0.130.75-0.390.740.870.890.590.990.090.750.72
0.830.680.640.690.62-0.270.870.730.590.820.57-0.130.290.63-0.280.77-0.450.810.690.810.710.71-0.190.750.73
0.940.660.910.710.91-0.50.740.940.640.810.430.00.370.69-0.10.99-0.350.70.580.840.580.71-0.470.720.73
Click cells to compare fundamentals

Kala Pharmaceuticals Account Relationship Matchups

Kala Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets154.3M221.6M139.4M86.8M55.9M53.2M
Total Current Liabilities24.8M22.2M37.4M25.7M8.3M7.9M
Total Stockholder Equity29.7M100.0M16.8M19.0M7.5M7.1M
Net Tangible Assets29.7M100.0M16.8M19.0M21.8M21.4M
Retained Earnings(295.5M)(399.8M)(542.4M)(587.2M)(629.4M)(597.9M)
Accounts Payable2.5M1.7M2.8M2.3M919K873.1K
Cash85.4M77.3M92.1M70.5M50.9M79.6M
Other Assets16.4M47.1M11.0M462K531.3K504.7K
Long Term Debt71.2M72.2M78.9M37.9M34.2M43.8M
Net Receivables13.1M9.9M17.5M6.5M236K224.2K
Common Stock Shares Outstanding684.2K1.0M1.3M1.5M2.4M2.6M
Other Current Assets1.6M2.8M6.1M9.0M1.7M2.5M
Total Liab124.6M121.6M122.6M67.8M48.4M91.9M
Total Current Assets105.5M171.4M124.4M85.9M52.9M98.6M
Short Term Debt1.3M3.1M1.4M5.0M668K634.6K
Common Stock36K59K66K2K3K2.9K
Property Plant Equipment32.5M9.4M4.0M416K478.4K454.5K
Short Long Term Debt Total101.2M100.9M80.2M43.0M36.3M61.0M
Other Current Liab20.9M17.4M33.2M14.1M5.7M5.4M
Property Plant And Equipment Net32.5M31.0M4.0M416K2.8M2.6M
Net Debt15.7M23.7M(11.9M)(27.5M)(14.6M)(15.3M)
Non Current Assets Total48.8M50.2M15.1M878K3.1M2.9M
Non Currrent Assets Other3.8M6.2M9.6M462K301K286.0K
Cash And Short Term Investments85.4M153.5M92.1M70.5M50.9M96.5M
Common Stock Total Equity25K34K36K59K67.9K71.2K
Long Term Debt Total12.0M70.2M71.2M72.2M83.1M44.5M
Liabilities And Stockholders Equity154.3M221.6M139.4M86.8M55.9M53.2M
Non Current Liabilities Total99.9M99.4M85.2M42.2M40.1M59.2M
Capital Surpluse224.0M306.1M325.1M499.7M574.7M603.4M
Other Stockholder Equity325.1M499.7M559.1M606.2M636.9M373.2M
Property Plant And Equipment Gross32.5M31.0M6.9M1.6M3.9M3.7M
Accumulated Other Comprehensive Income(1.5M)(1.8M)(2.5M)4K4.6K4.8K
Inventory4.6M5.2M8.6M7.7M8.8M5.6M
Net Invested Capital100.9M172.2M95.7M61.9M41.7M39.6M
Net Working Capital80.7M149.2M86.9M60.3M44.5M78.0M
Capital Lease Obligations30M28.7M1.3M13K2.1M2.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Kala Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kala Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kala Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kala Pharmaceuticals Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kala Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kala Pharmaceuticals. If investors know Kala will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kala Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(11.67)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.40)
Return On Equity
(2.48)
The market value of Kala Pharmaceuticals is measured differently than its book value, which is the value of Kala that is recorded on the company's balance sheet. Investors also form their own opinion of Kala Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kala Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kala Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kala Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kala Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kala Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kala Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.